Castle Hook Partners’s PTC Therapeutics PTCT Stock Holding History

Castle Hook Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-30,000	Closed	-$1.01M	–	53
2019 Q3	$1.01M	Buy	+30,000	New	+$1.31M	0.03%	37

Other funds holding PTCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Castle Hook Partners's PTCT Position: Q4 2019 in Review

Castle Hook Partners sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 30,000 shares — an estimated $1.01M sold.

Castle Hook Partners first reported a position in PTCT in Q3 2019 and held it in 1 quarter. The position peaked at $1.01M in Q3 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

Castle Hook Partners reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
Castle Hook Partners sold 30,000 PTC Therapeutics shares in Q4 2019, an estimated $1.01M.
Castle Hook Partners first reported a position in PTC Therapeutics in Q3 2019 and held it in 1 quarter.
Castle Hook Partners's PTC Therapeutics position peaked at $1.01M in Q3 2019.
206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Castle Hook Partners's 13F filing for Q4 2019, filed 14 Feb 2020.